I would say at some point we don’t even have to keep measuring all these things because we know they should be strongly correlated. Then we are seeing all of those comorbidities we talked about, we are seeing them improve as well, so we are seeing the depression, the anxiety, all these other markers. There’s sort of a starting dose, and then each one has a double dose that can be used, particularly if a few months in you’re not seeing what you would expect. We are seeing incredibly deep efficacy of these drugs, and of course both of these drugs we have in the United States have 2 dosing levels. As you might expect, we are seeing a very rapid improvement in all the symptoms and signs of atopic dermatitis for our oral JAK inhibitors. I think they are allowing us to access that for these patients. ![]() I think we’re hearing it today, it is so neat, what we used to settle for even just 5 or 10 years ago, “Hopefully we’ll cool you down for a bit, get you a little better.” Now we’re saying, “I want you clear, and then I want you clear safely going forward,” and ideally, we want people to be able to keep this up indefinitely. We also are adjusting our treatment to its target. We are learning more about atopic dermatitis and all of its comorbidities and how these run together. Lio, MD: I think what we’re seeing in general with these new oral medicines is what I like to call the virtuous cycle of drug development. Can you run us through what have we seen in terms of efficacy and quality of life there? ![]() Peter, you certainly alluded to the fact that we have these oral agents. Linda Stein Gold, MD: We’ve had a great talk about the topical agent.
0 Comments
Leave a Reply. |